Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.

Patterson JR, Duffy MF, Kemp CJ, Howe JW, Collier TJ, Stoll AC, Miller KM, Patel P, Levine N, Moore DJ, Luk KC, Fleming SM, Kanaan NM, Paumier KL, El-Agnaf OMA, Sortwell CE.

Neurobiol Dis. 2019 Oct;130:104525. doi: 10.1016/j.nbd.2019.104525. Epub 2019 Jul 2.

2.

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo.

Patterson JR, Polinski NK, Duffy MF, Kemp CJ, Luk KC, Volpicelli-Daley LA, Kanaan NM, Sortwell CE.

J Vis Exp. 2019 Jun 2;(148). doi: 10.3791/59758.

PMID:
31205308
3.

Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson's Disease.

Duffy MF, Collier TJ, Patterson JR, Kemp CJ, Fischer DL, Stoll AC, Sortwell CE.

Front Neurosci. 2018 Sep 4;12:621. doi: 10.3389/fnins.2018.00621. eCollection 2018.

4.

Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancer.

Ishibashi M, Toyoshima M, Zhang X, Hasegawa-Minato J, Shigeta S, Usui T, Kemp CJ, Grandori C, Kitatani K, Yaegashi N.

Sci Rep. 2018 Sep 4;8(1):13207. doi: 10.1038/s41598-018-31069-2.

5.

Personalized Cancer Models for Target Discovery and Precision Medicine.

Grandori C, Kemp CJ.

Trends Cancer. 2018 Sep;4(9):634-642. doi: 10.1016/j.trecan.2018.07.005. Epub 2018 Aug 8. Review.

6.

CDK12: an emerging therapeutic target for cancer.

Lui GYL, Grandori C, Kemp CJ.

J Clin Pathol. 2018 Nov;71(11):957-962. doi: 10.1136/jclinpath-2018-205356. Epub 2018 Aug 13. Review.

7.

Correction to: Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration.

Duffy MF, Collier TJ, Patterson JR, Kemp CJ, Luk KC, Tansey MG, Paumier KL, Kanaan NM, Fischer DL, Polinski NK, Barth OL, Howe JW, Vaikath NN, Majbour NK, El-Agnaf OMA, Sortwell CE.

J Neuroinflammation. 2018 May 29;15(1):169. doi: 10.1186/s12974-018-1202-9.

8.

Bdnf variant is associated with milder motor symptom severity in early-stage Parkinson's disease.

Fischer DL, Auinger P, Goudreau JL, Paumier KL, Cole-Strauss A, Kemp CJ, Lipton JW, Sortwell CE.

Parkinsonism Relat Disord. 2018 Aug;53:70-75. doi: 10.1016/j.parkreldis.2018.05.003. Epub 2018 May 9.

PMID:
29759928
9.

Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration.

Duffy MF, Collier TJ, Patterson JR, Kemp CJ, Luk KC, Tansey MG, Paumier KL, Kanaan NM, Fischer DL, Polinski NK, Barth OL, Howe JW, Vaikath NN, Majbour NK, El-Agnaf OMA, Sortwell CE.

J Neuroinflammation. 2018 May 1;15(1):129. doi: 10.1186/s12974-018-1171-z. Erratum in: J Neuroinflammation. 2018 May 29;15(1):169.

10.

Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer.

Xu C, Nikolova O, Basom RS, Mitchell RM, Shaw R, Moser RD, Park H, Gurley KE, Kao MC, Green CL, Schaub FX, Diaz RL, Swan HA, Jang IS, Guinney J, Gadi VK, Margolin AA, Grandori C, Kemp CJ, Méndez E.

Clin Cancer Res. 2018 Jun 15;24(12):2828-2843. doi: 10.1158/1078-0432.CCR-17-1339. Epub 2018 Mar 29.

11.

DNA-PK, ATM, and ATR: PIKKing on p53.

Ashley AK, Kemp CJ.

Cell Cycle. 2018;17(3):275-276. doi: 10.1080/15384101.2017.1412147. Epub 2018 Apr 2. No abstract available.

12.

Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein Overexpression.

Fischer DL, Manfredsson FP, Kemp CJ, Cole-Strauss A, Lipton JW, Duffy MF, Polinski NK, Steece-Collier K, Collier TJ, Gombash SE, Buhlinger DJ, Sortwell CE.

Sci Rep. 2017 Nov 27;7(1):16356. doi: 10.1038/s41598-017-16690-x.

13.

Nonmonotonic Pathway Gene Expression Analysis Reveals Oncogenic Role of p27/Kip1 at Intermediate Dose.

Nguyen HH, Tilton SC, Kemp CJ, Song M.

Cancer Inform. 2017 Nov 13;16:1176935117740132. doi: 10.1177/1176935117740132. eCollection 2017.

14.

Synergy between Prkdc and Trp53 regulates stem cell proliferation and GI-ARS after irradiation.

Gurley KE, Ashley AK, Moser RD, Kemp CJ.

Cell Death Differ. 2017 Nov;24(11):1853-1860. doi: 10.1038/cdd.2017.107. Epub 2017 Jul 7.

15.

Subthalamic Nucleus Deep Brain Stimulation Employs trkB Signaling for Neuroprotection and Functional Restoration.

Fischer DL, Kemp CJ, Cole-Strauss A, Polinski NK, Paumier KL, Lipton JW, Steece-Collier K, Collier TJ, Buhlinger DJ, Sortwell CE.

J Neurosci. 2017 Jul 12;37(28):6786-6796. doi: 10.1523/JNEUROSCI.2060-16.2017. Epub 2017 Jun 12.

16.

Assessing Biobehavioural Self-Regulation and Coregulation in Early Childhood: The Parent-Child Challenge Task.

Lunkenheimer E, Kemp CJ, Lucas-Thompson RG, Cole PM, Albrecht EC.

Infant Child Dev. 2017 Jan-Feb;26(1). pii: e1965. doi: 10.1002/icd.1965. Epub 2016 Apr 5.

17.

Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.

Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R, McNary TJ, Churakova Y, Cheung C, Triscott J, Pisapia D, Rao R, Mosquera JM, Robinson B, Faltas BM, Emerling BE, Gadi VK, Bernard B, Elemento O, Beltran H, Demichelis F, Kemp CJ, Grandori C, Cantley LC, Rubin MA.

Cancer Discov. 2017 May;7(5):462-477. doi: 10.1158/2159-8290.CD-16-1154. Epub 2017 Mar 22.

18.

Breaking Down the Coercive Cycle: How Parent and Child Risk Factors Influence Real-Time Variability in Parental Responses to Child Misbehavior.

Lunkenheimer E, Lichtwarck-Aschoff A, Hollenstein T, Kemp CJ, Granic I.

Parent Sci Pract. 2016;16(4):237-256. doi: 10.1080/15295192.2016.1184925. Epub 2016 Aug 23.

19.

Can We Fix This? Parent-Child Repair Processes and Preschoolers' Regulatory Skills.

Kemp CJ, Lunkenheimer E, Albrecht EC, Chen D.

Fam Relat. 2016 Oct;65(4):576-590. doi: 10.1111/fare.12213. Epub 2016 Sep 16.

20.

Impact of age and vector construct on striatal and nigral transgene expression.

Polinski NK, Manfredsson FP, Benskey MJ, Fischer DL, Kemp CJ, Steece-Collier K, Sandoval IM, Paumier KL, Sortwell CE.

Mol Ther Methods Clin Dev. 2016 Dec 7;3:16082. eCollection 2016.

21.

Viral Vector-Based Modeling of Neurodegenerative Disorders: Parkinson's Disease.

Fischer DL, Gombash SE, Kemp CJ, Manfredsson FP, Polinski NK, Duffy MF, Sortwell CE.

Methods Mol Biol. 2016;1382:367-82. doi: 10.1007/978-1-4939-3271-9_26.

PMID:
26611600
22.

Animal Models of Chemical Carcinogenesis: Driving Breakthroughs in Cancer Research for 100 Years.

Kemp CJ.

Cold Spring Harb Protoc. 2015 Oct 1;2015(10):865-74. doi: 10.1101/pdb.top069906.

23.

Induction of Liver Tumors in Mice with N-Ethyl-N-Nitrosourea or N-Nitrosodiethylamine.

Gurley KE, Moser RD, Kemp CJ.

Cold Spring Harb Protoc. 2015 Oct 1;2015(10):941-2. doi: 10.1101/pdb.prot077438.

PMID:
26430250
24.

Induction of Colon Cancer in Mice with 1,2-Dimethylhydrazine.

Gurley KE, Moser RD, Kemp CJ.

Cold Spring Harb Protoc. 2015 Sep 1;2015(9):pdb.prot077453. doi: 10.1101/pdb.prot077453.

PMID:
26330619
25.

Induction of Lung Tumors in Mice with Urethane.

Gurley KE, Moser RD, Kemp CJ.

Cold Spring Harb Protoc. 2015 Sep 1;2015(9):pdb.prot077446. doi: 10.1101/pdb.prot077446.

PMID:
26330618
26.

High-Frequency Stimulation of the Rat Entopeduncular Nucleus Does Not Provide Functional or Morphological Neuroprotection from 6-Hydroxydopamine.

Fischer DL, Collier TJ, Cole-Strauss A, Wohlgenant SL, Lipton JW, Steece-Collier K, Manfredsson FP, Kemp CJ, Sortwell CE.

PLoS One. 2015 Jul 29;10(7):e0133957. doi: 10.1371/journal.pone.0133957. eCollection 2015.

27.

Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.

Paumier KL, Luk KC, Manfredsson FP, Kanaan NM, Lipton JW, Collier TJ, Steece-Collier K, Kemp CJ, Celano S, Schulz E, Sandoval IM, Fleming S, Dirr E, Polinski NK, Trojanowski JQ, Lee VM, Sortwell CE.

Neurobiol Dis. 2015 Oct;82:185-199. doi: 10.1016/j.nbd.2015.06.003. Epub 2015 Jun 17.

28.

Anthracyclines induce double-strand DNA breaks at active gene promoters.

Yang F, Kemp CJ, Henikoff S.

Mutat Res. 2015 Mar;773:9-15.

29.

Identification of a novel E-box binding pyrrole-imidazole polyamide inhibiting MYC-driven cell proliferation.

Mishra R, Watanabe T, Kimura MT, Koshikawa N, Ikeda M, Uekusa S, Kawashima H, Wang X, Igarashi J, Choudhury D, Grandori C, Kemp CJ, Ohira M, Verma NK, Kobayashi Y, Takeuchi J, Koshinaga T, Nemoto N, Fukuda N, Soma M, Kusafuka T, Fujiwara K, Nagase H.

Cancer Sci. 2015 Apr;106(4):421-9. doi: 10.1111/cas.12610. Epub 2015 Mar 3.

30.

Recombinant adenoassociated virus 2/5-mediated gene transfer is reduced in the aged rat midbrain.

Polinski NK, Gombash SE, Manfredsson FP, Lipton JW, Kemp CJ, Cole-Strauss A, Kanaan NM, Steece-Collier K, Kuhn NC, Wohlgenant SL, Sortwell CE.

Neurobiol Aging. 2015 Feb;36(2):1110-20. doi: 10.1016/j.neurobiolaging.2014.07.047. Epub 2014 Oct 13.

31.

The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.

Westcott PM, Halliwill KD, To MD, Rashid M, Rust AG, Keane TM, Delrosario R, Jen KY, Gurley KE, Kemp CJ, Fredlund E, Quigley DA, Adams DJ, Balmain A.

Nature. 2015 Jan 22;517(7535):489-92. doi: 10.1038/nature13898. Epub 2014 Nov 2.

32.

Functional kinomics identifies candidate therapeutic targets in head and neck cancer.

Moser R, Xu C, Kao M, Annis J, Lerma LA, Schaupp CM, Gurley KE, Jang IS, Biktasova A, Yarbrough WG, Margolin AA, Grandori C, Kemp CJ, Méndez E.

Clin Cancer Res. 2014 Aug 15;20(16):4274-88. doi: 10.1158/1078-0432.CCR-13-2858.

33.

Tumors induce coordinate growth of artery, vein, and lymphatic vessel triads.

Ruddell A, Croft A, Kelly-Spratt K, Furuya M, Kemp CJ.

BMC Cancer. 2014 May 21;14:354. doi: 10.1186/1471-2407-14-354.

34.

Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways.

Gombash SE, Manfredsson FP, Mandel RJ, Collier TJ, Fischer DL, Kemp CJ, Kuhn NM, Wohlgenant SL, Fleming SM, Sortwell CE.

Gene Ther. 2014 Jul;21(7):682-93. doi: 10.1038/gt.2014.42. Epub 2014 May 8.

35.

CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer.

Kemp CJ, Moore JM, Moser R, Bernard B, Teater M, Smith LE, Rabaia NA, Gurley KE, Guinney J, Busch SE, Shaknovich R, Lobanenkov VV, Liggitt D, Shmulevich I, Melnick A, Filippova GN.

Cell Rep. 2014 May 22;7(4):1020-9. doi: 10.1016/j.celrep.2014.04.004. Epub 2014 May 1.

36.

Doxorubicin, DNA torsion, and chromatin dynamics.

Yang F, Teves SS, Kemp CJ, Henikoff S.

Biochim Biophys Acta. 2014 Jan;1845(1):84-9. doi: 10.1016/j.bbcan.2013.12.002. Epub 2013 Dec 19. Review.

37.

Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system.

Gombash SE, Manfredsson FP, Kemp CJ, Kuhn NC, Fleming SM, Egan AE, Grant LM, Ciucci MR, MacKeigan JP, Sortwell CE.

PLoS One. 2013 Nov 27;8(11):e81426. doi: 10.1371/journal.pone.0081426. eCollection 2013.

38.

Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer.

Diede SJ, Yao Z, Keyes CC, Tyler AE, Dey J, Hackett CS, Elsaesser K, Kemp CJ, Neiman PE, Weiss WA, Olson JM, Tapscott SJ.

Epigenetics. 2013 Dec;8(12):1254-60. doi: 10.4161/epi.26486. Epub 2013 Oct 9.

39.

Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity.

Huang JW, Wang Y, Dhillon KK, Calses P, Villegas E, Mitchell PS, Tewari M, Kemp CJ, Taniguchi T.

Mol Cancer Res. 2013 Dec;11(12):1564-73. doi: 10.1158/1541-7786.MCR-13-0292. Epub 2013 Oct 2.

40.
41.

ARF inhibits the growth and malignant progression of non-small-cell lung carcinoma.

Busch SE, Moser RD, Gurley KE, Kelly-Spratt KS, Liggitt HD, Kemp CJ.

Oncogene. 2014 May 15;33(20):2665-73. doi: 10.1038/onc.2013.208. Epub 2013 Jun 10.

42.
43.

Doxorubicin enhances nucleosome turnover around promoters.

Yang F, Kemp CJ, Henikoff S.

Curr Biol. 2013 May 6;23(9):782-7. doi: 10.1016/j.cub.2013.03.043. Epub 2013 Apr 18.

44.

Functional genomics to identify unforeseen cancer drug targets.

Kemp CJ, Grandori C.

Future Oncol. 2013 Apr;9(4):473-6. doi: 10.2217/fon.13.26. No abstract available.

PMID:
23560369
45.

Controlling proteome degradation in Daphnia pulex.

Kemp CJ, Kültz D.

J Exp Zool A Ecol Genet Physiol. 2012 Dec;317(10):645-51. doi: 10.1002/jez.1766. Epub 2012 Oct 1.

46.

MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition.

Wang Y, Huang JW, Calses P, Kemp CJ, Taniguchi T.

Cancer Res. 2012 Aug 15;72(16):4037-46. doi: 10.1158/0008-5472.CAN-12-0103. Epub 2012 Jul 3.

47.

Loss of maternal CTCF is associated with peri-implantation lethality of Ctcf null embryos.

Moore JM, Rabaia NA, Smith LE, Fagerlie S, Gurley K, Loukinov D, Disteche CM, Collins SJ, Kemp CJ, Lobanenkov VV, Filippova GN.

PLoS One. 2012;7(4):e34915. doi: 10.1371/journal.pone.0034915. Epub 2012 Apr 20.

48.

ARF suppresses hepatic vascular neoplasia in a carcinogen-exposed murine model.

Busch SE, Gurley KE, Moser RD, Kemp CJ.

J Pathol. 2012 Jul;227(3):298-305. doi: 10.1002/path.4024. Epub 2012 May 8.

49.

Subthalamic nucleus stimulation increases brain derived neurotrophic factor in the nigrostriatal system and primary motor cortex.

Spieles-Engemann AL, Steece-Collier K, Behbehani MM, Collier TJ, Wohlgenant SL, Kemp CJ, Cole-Strauss A, Levine ND, Gombash SE, Thompson VB, Lipton JW, Sortwell CE.

J Parkinsons Dis. 2011;1(1):123-36.

50.

MYC-driven tumorigenesis is inhibited by WRN syndrome gene deficiency.

Moser R, Toyoshima M, Robinson K, Gurley KE, Howie HL, Davison J, Morgan M, Kemp CJ, Grandori C.

Mol Cancer Res. 2012 Apr;10(4):535-45. doi: 10.1158/1541-7786.MCR-11-0508. Epub 2012 Feb 1.

Supplemental Content

Support Center